Q4 2022 Results

Company overview Innovation: Pipeline overview Cardiovascular KisqaliⓇ - CDK4 inhibitor Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience NCT03701334 NATALEE (CLEE011012301C) Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Readout Milestone(s) Adjuvant treatment of hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC) Phase 3 5101 Invasive Disease-Free Survival for using STEEP criteria (Standardized Definitions for Efficacy End Points in adjuvant breast cancer trials) Ribociclib endocrine therapy Endocrine therapy Pre and postmenopausal women and men with HR-positive, HER2-negative EBC, after adequate surgical resection, who are eligible for adjuvant endocrine therapy 2023 Publication TBD 87 Investor Relations | Q4 2022 Results Oncology Appendix Abbreviations Other NOVARTIS | Reimagining Medicine

View entire presentation